
Please try another search
Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, which are in the pre-clinical stage to treat glioblastoma (brain cancer), as well as have completed the pre-clinical stage for the treatment of non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company also develops uTRACE diagnostic solutions, which are in Phase II to treat prostate cancer, as well as have completed Phase II for the treatment of glioblastoma (brain cancer), prostate cancer, neuroendocrine neoplasms, head and neck cancer, non-small cell lung cancer, and urinary bladder cancer. Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Ulrich Alexander Krasilnikoff | 57 | 2016 | CEO, CFO & Executive Director |
Lars Trolle | 57 | 2014 | Independent Deputy Chairman of the Board |
Kirsten Aarup Drejer | 68 | 2021 | Chairman of the Board |
Charlotte Vedel | 57 | 2020 | Independent Director |
Andreas Kjaer | 62 | 2013 | Co-Founder, Chief Scientific Officer, Chief Medical Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review